Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study - Concepedia

Concepedia

Publication | Open Access

Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study

DOI Full Paper Access

13

Citations

20

References

2024

Year

Thomas O. Crawford, John Day, Darryl C. De Vivo, Jena M. Krueger, Eugenio Mercuri, A. Nascimento, Amy Pasternak, Elena Mazzone, Tina Duong, Guochen Song,

Frontiers in Neurology

Abstract

The benefit of apitegromab treatment observed at 12 months was sustained at 36 months with no new safety findings.

References

	Year	Citations

Page 1